Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

@article{Simon2008PemetrexedPG,
  title={Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.},
  author={George Rajan Simon and Claire F. Verschraegen and Pasi Antero J{\"a}nne and Corey J. Langer and Afshin Dowlati and Shirish M. Gadgeel and Karen Kelly and Gregory P. Kalemkerian and Anne M. Traynor and Guangbin Peng and John F. Gill and Coleman K. Obasaju and Hedy Lee Kindler},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 21},
  pages={3567-72}
}
PURPOSE Pemetrexed in combination with cisplatin is approved for the treatment of pleural mesothelioma and is active in malignant peritoneal mesothelioma (MPeM). Pemetrexed and gemcitabine are synergistic in preclinical models, but the activity of this combination in MPeM is unknown. This clinical study assessed safety and efficacy of pemetrexed plus… CONTINUE READING